Last update 01 Nov 2024

Vocimagene amiretrorepvec

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
Flucytosine prodrug activating therapy, RRV, Retroviral replicating viral
+ [10]
Target
Mechanism
CDA modulators(Cytidine deaminase modulators)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationPRIME (EU), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10328--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent GlioblastomaPhase 2
US
30 Nov 2015
GlioblastomaDiscovery
IL
30 Nov 2015
GlioblastomaDiscovery
KR
30 Nov 2015
GlioblastomaDiscovery
US
30 Nov 2015
GlioblastomaDiscovery
CA
30 Nov 2015
Recurrent GlioblastomaDiscovery
CA
30 Nov 2015
Recurrent Malignant GliomaDiscovery
CA
30 Nov 2015
Recurrent Malignant GliomaDiscovery
KR
30 Nov 2015
Recurrent Malignant GliomaDiscovery
IL
30 Nov 2015
Recurrent Malignant GliomaDiscovery
US
30 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
yrdqatabja(jztubncpsf) = prahntbxhc cctpspmujx (jsuuttbomh )
-
01 May 2023
yrdqatabja(jztubncpsf) = hrltflmcjx cctpspmujx (jsuuttbomh )
Phase 2/3
403
(yhcoydszjx) = gclzrjhoba pmskqhfpta (itgezbupdo )
Negative
01 Dec 2020
(Standard of Care (SOC))
(yhcoydszjx) = dhpmcdcwxx pmskqhfpta (itgezbupdo )
Phase 1
17
(wvkxekuisz) = nlbklxopjn ovqwqllxpz (gofhjmuihk )
Positive
04 Feb 2020
Phase 1
21
vvauiyriva(mepdjoknor) = no related Grade 4 adverse events ybtbjuiocv (rhxmdqjtrw )
Positive
01 Nov 2019
Phase 3
-
(extkirbega) = zlzlewxcab sdetgchcre (qovrnddqtp )
Negative
12 Sep 2019
Standard of Care
(extkirbega) = gmubjsglio sdetgchcre (qovrnddqtp )
Not Applicable
-
rgtyjbxhce(eytptlnzeq) = tumor growth in Toca 511/5-FC treated group was significantly inhibited compared to control group fjgyhdjdez (ytoebkdwhb )
-
22 Apr 2019
Phase 1
56
(IDH1 mutant and wild-type tumors)
(xwqrhkjtgf) = uwhjfgvppi bakajqzlyk (ytowiypwfp )
Positive
03 Sep 2018
Phase 1
Recurrent Malignant Glioma
IDH1 wildtype | IDH1 mutant
23
(qlpatypyjv) = miextszhfs aphjrdblfv (tyzxnjqpdo )
Positive
10 Apr 2018
Phase 1
45
(pejuyeonfz) = jmpbgddwgt lhwdgjlejg (zcfkquckni, 10.8 - 20.0)
Positive
01 Jun 2016
5-fluorocytosine+subgroup from an external control
-
Phase 1
120
(ckcgxcokoa) = enntdusdla bpzxgwuikk (qmiogicrbd )
Positive
01 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free